Musa Ajala, MD
Nephrology · Findlay, OHNPI 1902889942
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,017 of the $1,291 with a category attached, or 78.8%. 14 manufacturers reported payments, led by Vifor Pharma, Inc. at 30.3% of the total. Reporting peaked in 2021 at $480 and has fallen 70.2% since, to $143 in 2025.
Across 61 payments — averaging $21.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$391
- Travere Therapeutics, Inc.$214
- Bayer$146
- Akebia Therapeutics Inc$121
- Mallinckrodt Hospital Products Inc.$81
- AstraZeneca$81
- plus $256 from 8 others
What the payments were for
- Food & beverage$1,01779%
- Education$27421%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 14 | $391 |
| Travere Therapeutics, Inc. | 12 | $214 |
| Bayer | 7 | $146 |
| Akebia Therapeutics Inc | 8 | $121 |
| Mallinckrodt Hospital Products Inc. | 4 | $81 |
| AstraZeneca | 4 | $81 |
| Otsuka America Pharmaceutical, Inc. | 3 | $68 |
| OPKO Pharmaceuticals, LLC | 2 | $39 |
| Novartis | 2 | $32 |
| Calliditas Therapeutics US Inc. | 1 | $30 |
| Gilead | 1 | $25 |
| Amgen | 1 | $24 |
| Fresenius USA Marketing, Inc. | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
How this compares
$1,291 in reported general payments places this provider in the 55th percentile of 450 nephrology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Potassium Citrate ErPotassium Citrate | 67 | $16,135 |
| Sevelamer Carbonate | 37 | $11,224 |
| ClinisolParenteral Amino Acid 15% No.5 | 53 | $9,136 |
| Midodrine Hcl | 44 | $7,928 |
| Bumetanide | 118 | $2,638 |
| Potassium Chloride | 76 | $1,780 |
| Allopurinol | 201 | $1,442 |
| Calcium Acetate | 18 | $1,402 |
| Losartan Potassium | 67 | $949 |
| Calcitriol | 54 | $848 |
| Furosemide | 102 | $592 |
| Lisinopril | 86 | $572 |
| Nifedipine ErNifedipine | 17 | $479 |
| Tamsulosin Hcl | 51 | $444 |
| Amlodipine Besylate | 83 | $437 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Findlay
- Brad RovinColumbus$379K
- Nissreen ElfadawyChardon$327K
- Andrew LazarBeachwood$315K
- Amit GovilCincinnati$298K
- Georges NakhoulCleveland$255K
- Sankar NavaneethanCleveland$253K
- Ibrahim AhmadKettering$232K
- Prabir Roy ChaudhuryCincinnati$205K
- Rupesh RainaAkron$163K
- Sevag DemirjianCleveland$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.